SHAILY
Shaily Engineering Plastics share price & financials
- Price
- ₹2,760.6
- Market cap
- ₹15.6k Cr
- Sector
- Consumer Durables
- Calls analysed
- 6
Shaily Engineering Plastics Limited Q1 FY27
What went well
- Consolidated revenue grew 14% YoY to INR 281 crores, up from INR 247 crores in Q1 FY26.
- EBITDA increased 18% YoY to INR 83 crores from INR 70 crores, with EBITDA margin expanding 120 bps to 29.7%.
- PAT grew 17% YoY to INR 48 crores from INR 41 crores, with PAT margin improving by 40 bps to 17.1%.
What to watch
- Consumer segment revenue declined 24% YoY to INR 116 crores due to softer demand in home furnishings in Europe and US.
- Gross margin declined sequentially due to increased commodity prices, freight costs, and premium freight incidents, though expected to normalize by Q3.
What Shaily Engineering Plastics Limited does
Shaily Engineering Plastics designs and manufactures precision injection-moulded plastic and metal components across three segments — Consumer, Industrial, and Healthcare — for OEM customers in India and over 35 export markets. Its Healthcare vertical makes drug-delivery devices such as pen injectors, auto-injectors, platform devices and pharma packaging, built around its own Shaily Harmony, Shaily Neo, Toby and Protean device platforms for GLP-1, insulin and other injectable therapies. The Consumer and Industrial businesses supply home-furnishing, FMCG-packaging, carbon-steel-furniture, LED-lighting, automotive, appliance and toy components. It runs mixed-material manufacturing (plastics plus steel) that lets a single facility serve a customer's full component set, supported by a UK-based innovation subsidiary, Shaily Innovations Limited, for design and drug-delivery R&D.
Segments
- Healthcare
- Consumer
- Industrial
- Manufacturing facilities
- 7 (Gujarat: 6 for plastics + 1 for steel furniture)
- Injection moulding machines
- 200+, ranging 35–1,000 tons
- Employees
- 2,000+
- Export markets
- 35+ countries
- Market position
- India's largest exporter of plastics components
- Global quality & compliance certifications
- 12, incl. ISO 9001, IATF 16949, ISO 13485, ISO 15378, MDSAP, ISO 14001, ISO 50001, RBA, AEO, ISCC Plus
Guidance record · Q1 FY27
what the last two calls moved 18 tracked 3 delivered 1 missed 14 open- Healthcare Revenue Contribution delivered said Q4 FY25 Promised: Medical device business will comprise about 30% of our revenues over the next few years. Q1 FY27: Healthcare revenue contributed 51% of consolidated revenue for the quarter, continuing to significantly exceed the target.
- Pen Sales Volume went quiet said Q4 FY25 Promised: Selling close to somewhere between 30 million to 35 million pens this year (FY26). Q1 FY27: Promise pertains to FY26, which has passed. No update provided on the final FY26 number.
- Semaglutide Pen Capacity Addition delayed said Q4 FY26 Promised: The additional 25 million that will come in by July, August is purely for Semaglutide. Q1 FY27: The timeline has been slightly pushed. Management now expects the capacity to be operational by the end of September.
All 18 tracked — every revision, and every one management stopped mentioning.
Open the guidance ledgerQuarterly results
Q1 FY27: revenue up 13.8%, net profit up 17.1% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 192 | 198 | 218 | 247 | 257 +34% | 250 +26% | 237 +9% | 281 +14% |
| EBITDA | 40 | 46 | 54 | 68 | 79 +98% | 66 +43% | 66 +22% | 83 +22% |
| Net profit | 22 | 25 | 29 | 41 | 51 +132% | 37 +48% | 40 +38% | 48 +17% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Performance +46.0% 1Y
1Y: ₹2,246.9 on 10 Sept 2025 → ₹3,279.5. High ₹3,457.9 (11 Aug 2026), low ₹1,821.6 (29 Jan 2026).
How the price took the results
close before → close after
- Q1 FY27
- +6.5%
- 10 Aug
- Q4 FY26
- +3.7%
- 20 May
- Q3 FY26
- −7.4%
- 13 Feb
- Q2 FY26
- −0.2%
- 10 Nov
The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.
Financials, as filed
Revenue grew 17.8% a year over 3 years, FY23 to FY26. Operating margin widened to 28.2%.
| Year ending | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹606 Cr | ₹644 Cr | ₹787 Cr | ₹991 Cr |
| Operating profit | ₹91 Cr | ₹118 Cr | ₹175 Cr | ₹279 Cr |
| Operating margin | 15.0% | 18.3% | 22.2% | 28.2% |
| Interest | ₹18 Cr | ₹18 Cr | ₹17 Cr | ₹16 Cr |
| Depreciation | ₹34 Cr | ₹35 Cr | ₹42 Cr | ₹49 Cr |
| Net profit | ₹34 Cr | ₹58 Cr | ₹93 Cr | ₹169 Cr |
| Net margin | 5.6% | 9.0% | 11.8% | 17.1% |
| Cash from operations | ₹90 Cr | ₹92 Cr | ₹110 Cr | ₹226 Cr |
| Free cash flow | ₹-22 Cr | ₹-3 Cr | ₹38 Cr | ₹41 Cr |
| ROCE | 11.0% | 14.0% | 20.0% | 29.0% |
How to read this
From the company's own filings. Margins are computed from the filed sums; a year with an incomplete quarter is left blank rather than estimated.
Balance sheet
| Year ending | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Equity capital | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr | ₹9 Cr |
| Reserves | ₹358 Cr | ₹392 Cr | ₹450 Cr | ₹626 Cr | ₹707 Cr |
| Borrowings | ₹175 Cr | ₹188 Cr | ₹209 Cr | ₹189 Cr | ₹177 Cr |
| Other liabilities | ₹135 Cr | ₹103 Cr | ₹114 Cr | ₹230 Cr | ₹253 Cr |
| Total liabilities | ₹677 Cr | ₹693 Cr | ₹782 Cr | ₹1.1k Cr | ₹1.1k Cr |
| Fixed assets | ₹333 Cr | ₹367 Cr | ₹473 Cr | ₹556 Cr | ₹620 Cr |
| Capital work in progress | ₹29 Cr | ₹68 Cr | ₹20 Cr | ₹21 Cr | ₹29 Cr |
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Other assets | ₹316 Cr | ₹257 Cr | ₹289 Cr | ₹478 Cr | ₹498 Cr |
| Total assets | ₹677 Cr | ₹693 Cr | ₹782 Cr | ₹1.1k Cr | ₹1.1k Cr |
How to read this
As filed each year. A line the company does not report — deposits for a non-lender, for instance — is left out rather than shown as a row of dashes.
Who owns it
As disclosed at Jun 2026
Since Jun 2025, FIIs added +8.47 pp while the public trimmed −6.53 pp. The shareholder count grew 140% to 56,755.
- Promoters
- 41.1%
- FIIs
- 18.2%
- DIIs
- 14.8%
- Public
- 25.9%
Since Jun 2025
- FIIs +8.47 pp
- Public −6.53 pp
- Promoters −2.63 pp
How it drifted, 12 quarters
Over this window FIIs went from 7.0% to 18.2% — +11.2 pp.
Ownership split by quarter, oldest first. Sep '23: Promoters 43.8%, FIIs 7.0%, DIIs 13.8%, Public 35.4%.Dec '23: Promoters 43.8%, FIIs 7.0%, DIIs 13.0%, Public 36.2%.Mar '24: Promoters 43.8%, FIIs 6.6%, DIIs 7.7%, Public 41.9%.Jun '24: Promoters 43.8%, FIIs 2.0%, DIIs 9.5%, Public 44.7%.Sep '24: Promoters 43.8%, FIIs 3.1%, DIIs 12.3%, Public 40.7%.Dec '24: Promoters 43.7%, FIIs 5.4%, DIIs 11.7%, Public 39.2%.Mar '25: Promoters 43.7%, FIIs 7.4%, DIIs 13.7%, Public 35.2%.Jun '25: Promoters 43.7%, FIIs 9.7%, DIIs 14.1%, Public 32.4%.Sep '25: Promoters 43.7%, FIIs 11.3%, DIIs 13.7%, Public 31.3%.Dec '25: Promoters 43.4%, FIIs 12.0%, DIIs 13.6%, Public 31.0%.Mar '26: Promoters 43.4%, FIIs 16.7%, DIIs 10.6%, Public 29.3%.Jun '26: Promoters 41.1%, FIIs 18.2%, DIIs 14.8%, Public 25.9%.
Who bought this quarter
since Mar 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- Bandhan Small Cap Fund Mutual fund +1.50 pp 3.47% held
- Aditya Birla Sun Life Trustee Private Limited A/C Aditya Birla Sun Life Small Cap Fund Mutual fund newly disclosed 1.14% held
- Motilal Oswal Special Opportunities Fund Mutual fund +0.79 pp 5.38% held
- Bofa Securities Europe Sa - Odi Foreign bank / ODI +0.56 pp 1.69% held
- Smallcap World Fund, Inc Global fund house +0.37 pp 7.80% held
The same filing shows 1 holder trimming and 1 off the list — both are in the register beside this.
Who is on the register
Named in the Jun 2026 filing
Every holder of Shaily Engineering Plastics Limited above SEBI's 1% disclosure line, and what changed since Mar 2026.
| Holder | Stake | Change |
|---|---|---|
| Tilottama Sanghvi | 14.00% | unchanged |
| Jayessh Mohanlal Shah | 8.29% | unchanged |
| Smallcap World Fund, Inc Global fund house | 7.80% | +0.37 pp |
| Mahendra Bhogilal Sanghvi | 7.24% | unchanged |
| Motilal Oswal Special Opportunities Fund Mutual fund | 5.38% | +0.79 pp |
| Laxman Sanghvi | 5.07% | unchanged |
| Bandhan Small Cap Fund Mutual fund | 3.47% | +1.50 pp |
| Ashish Kacholia | 3.22% | unchanged |
| Shaily Mahendra Sanghvi | 2.83% | unchanged |
| Amit Mahendra Sanghvi | 2.62% | unchanged |
| Suryavanshi Commotrade Private Limited | 1.99% | unchanged |
| Bofa Securities Europe Sa - Odi Foreign bank / ODI | 1.69% | +0.56 pp |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
What the price assumes
AttractiveTo justify its price of ₹3280, this stock must grow earnings at 41% every year for 7 years. Our analysis caps realistic growth at ~70%. At that growth it is worth ₹11096 — upside of 238%.
- Growth the price implies
- 41.4% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 69.6% a year
- net profit, FY23–FY26 · EPS 69.9%
- The gap
- -0.3 pp
- 238% downside if it only repeats history
All earnings calls (6)
Read the Q1 FY27 call →Learn to analyse Shaily Engineering Plastics Limited
Guides on how to read this kind of business and the numbers that matter.